Terminal Type-Specific Cannabinoid CB1 Receptor Alterations in Patients With Schizophrenia

Individuals with schizophrenia use cannabis at a higher rate than the general population and may experience disease symptom exacerbations when exposed to cannabis. The major psychoactive substance in cannabis delta-9-tetrahydrocannabinol, targets the cannabinoid CB1 receptor (CB1R). Thus far, studies examining CB1R alterations in schizophrenia have led to conflicting results. We recently demonstrated differential levels of CB1R present in excitatory and inhibitory boutons in the postmortem human prefrontal cortex.
Source: Biological Psychiatry - Category: Psychiatry Authors: Source Type: research